{"id":"alteplase","rwe":[],"_fda":{"id":"0c2938dd-2978-411f-bd76-208fc8754838","set_id":"91ecdef2-95ff-42dd-a31c-c8a09cab3ad9","openfda":{"unii":["1RXS4UE564"],"route":["INTRAVENOUS"],"spl_id":["0c2938dd-2978-411f-bd76-208fc8754838"],"brand_name":["Cathflo Activase"],"spl_set_id":["91ecdef2-95ff-42dd-a31c-c8a09cab3ad9"],"package_ndc":["50242-041-64","50242-041-10"],"product_ndc":["50242-041"],"generic_name":["ALTEPLASE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ALTEPLASE"],"manufacturer_name":["Genentech, Inc."],"application_number":["BLA103172"],"is_original_packager":[true]},"version":"18","warnings":["WARNINGS None."],"pregnancy":["Pregnancy Alteplase has been shown to have an embryocidal effect due to an increased postimplantation loss rate in rabbits when administered intravenously during organogenesis at a dose (3 mg/kg) approximately 50 times human exposure (based on AUC) at the dose for restoration of function to occluded CVADs. No maternal or fetal toxicity was evident at a dose (1 mg/kg) approximately 16 times human exposure at the dose for restoration of function to occluded CVADs. There are no adequate and well‑controlled studies in pregnant women. Cathflo Activase should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"references":["REFERENCES Collen D, Lijnen HR. Fibrinolysis and the control of hemostasis. In: Stamatoyannopoulos G, Nienhui AW, Majerus PW, Varmus H, editors. The molecular basis of blood diseases, 2nd edition. Philadelphia: Saunders, 1994:662–88. Tanswell P, Tebbe U, Neuhaus K-L, Glasle-Schwarz L, Wojick J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992;19:1071–5. Califf RM, Topol EJ, George BS, Boswick JM, Abbottsmith C, Sigmon KN, et al., and the Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med 1988;85:353–9. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI), phase II trial. Ann Int Med 1991;115:256–65."],"description":["DESCRIPTION Cathflo ® Activase ® (Alteplase) is a tissue plasminogen activator (t‑PA) produced by recombinant DNA technology. It is a sterile, purified glycoprotein of 527 amino acids. It is synthesized using the complementary DNA (cDNA) for natural human tissue‑type plasminogen activator (t‑PA) obtained from an established human cell line. The manufacturing process involves secretion of the enzyme Alteplase into the culture medium by an established mammalian cell line (Chinese hamster ovary cells) into which the cDNA for Alteplase has been genetically inserted. Cathflo Activase (Alteplase) for injection is a sterile, white to pale yellow, lyophilized powder for intracatheter instillation for restoration of function to central venous access devices following reconstitution with Sterile Water for Injection, USP. Each vial of Cathflo Activase contains 2.2 mg of Alteplase (which includes a 10% overfill), 77 mg of L‑arginine, 0.2 mg of polysorbate 80, and phosphoric acid for pH adjustment. Each reconstituted vial will deliver 2 mg of Cathflo Activase, at a pH of approximately 7.3."],"precautions":["PRECAUTIONS General Catheter dysfunction may be caused by a variety of conditions other than thrombus formation, such as catheter malposition, mechanical failure, constriction by a suture, and lipid deposits or drug precipitates within the catheter lumen. These types of conditions should be considered before treatment with Cathflo Activase. Because of the risk of damage to the vascular wall or collapse of soft‑walled catheters, vigorous suction should not be applied during attempts to determine catheter occlusion. Excessive pressure should be avoided when Cathflo Activase is instilled into the catheter. Such force could cause rupture of the catheter or expulsion of the clot into the circulation. Bleeding The most frequent adverse reaction associated with all thrombolytics in all approved indications is bleeding (3,4). Cathflo Activase has not been studied in patients known to be at risk for bleeding events that may be associated with the use of thrombolytics. Caution should be exercised with patients who have active internal bleeding or who have had any of the following within 48 hours: surgery, obstetrical delivery, percutaneous biopsy of viscera or deep tissues, or puncture of non‑compressible vessels. In addition, caution should be exercised with patients who have thrombocytopenia, other hemostatic defects (including those secondary to severe hepatic or renal disease), or any condition for which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location, or who are at high risk for embolic complications (e.g., venous thrombosis in the region of the catheter). Death and permanent disability have been reported in patients who have experienced stroke and other serious bleeding episodes when receiving pharmacologic doses of a thrombolytic. Should serious bleeding in a critical location (e.g., intracranial, gastrointestinal, retroperitoneal, pericardial) occur, treatment with Cathflo Activase should be stopped and the drug should be withdrawn from the catheter. Infections Cathflo Activase should be used with caution in the presence of known or suspected infection in the catheter. Using Cathflo Activase in patients with infected catheters may release a localized infection into the systemic circulation (see ADVERSE REACTIONS ). As with all catheterization procedures, care should be used to maintain aseptic technique. Hypersensitivity Hypersensitivity, including urticaria, angioedema and anaphylaxis, has been reported in association with use of Cathflo Activase. Monitor patients treated with Cathflo Activase for signs of hypersensitivity and treat appropriately if necessary. Re-Administration In clinical trials, patients received up to two 2 mg/2 mL doses (4 mg total) of Alteplase. Additional re-administration of Cathflo Activase has not been studied. Antibody formation in patients receiving one or more doses of Cathflo Activase for restoration of function to CVADs has not been studied. Drug Interactions The interaction of Cathflo Activase with other drugs has not been formally studied. Concomitant use of drugs affecting coagulation and/or platelet function has not been studied. Drug/Laboratory Test Interactions Potential interactions between Cathflo Activase and laboratory tests have not been studied. Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals have not been performed to evaluate the carcinogenic potential or the effect on fertility. Short-term studies that evaluated tumorigenicity of Alteplase and effect on tumor metastases were negative in rodents. Studies to determine mutagenicity (Ames test) and chromosomal aberration assays in human lymphocytes were negative at all concentrations tested. Cytotoxicity, as reflected by a decrease in mitotic index, was evidenced only after prolonged exposure at high concentrations exceeding those expected to be achieved with Cathflo Activase. Pregnancy Alteplase has been shown to have an embryocidal effect due to an increased postimplantation loss rate in rabbits when administered intravenously during organogenesis at a dose (3 mg/kg) approximately 50 times human exposure (based on AUC) at the dose for restoration of function to occluded CVADs. No maternal or fetal toxicity was evident at a dose (1 mg/kg) approximately 16 times human exposure at the dose for restoration of function to occluded CVADs. There are no adequate and well‑controlled studies in pregnant women. Cathflo Activase should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers It is not known whether Cathflo Activase is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cathflo Activase is administered to a nursing woman. Pediatric Use A total of 432 subjects under age 17 have received Cathflo Activase in the three trials. Rates of serious adverse events were similar in the pediatric and adult patients, as were the rates of catheter function restoration. Geriatric Use In 312 patients enrolled who were age 65 years and over, no incidents of intracranial hemorrhage (ICH), embolic events, or major bleeding events were observed. One hundred three of these patients were age 75 years and over, and 12 were age 85 years and over. The effect of Alteplase on common age-related comorbidities has not been studied. In general, caution should be used in geriatric patients with conditions known to increase the risk of bleeding (see PRECAUTIONS, Bleeding )."],"how_supplied":["HOW SUPPLIED Cathflo Activase (Alteplase) for injection is supplied as a sterile, lyophilized powder in 2 mg vials. Cathflo ® Activase ® is available in a carton that contains one 2 mg vial of Cathflo ® Activase ® (Alteplase): NDC 50242‑041‑64 or a carton that contains ten 2 mg vials of Cathflo ® Activase ® (Alteplase): NDC 50242-041-10."],"geriatric_use":["Geriatric Use In 312 patients enrolled who were age 65 years and over, no incidents of intracranial hemorrhage (ICH), embolic events, or major bleeding events were observed. One hundred three of these patients were age 75 years and over, and 12 were age 85 years and over. The effect of Alteplase on common age-related comorbidities has not been studied. In general, caution should be used in geriatric patients with conditions known to increase the risk of bleeding (see PRECAUTIONS, Bleeding )."],"pediatric_use":["Pediatric Use A total of 432 subjects under age 17 have received Cathflo Activase in the three trials. Rates of serious adverse events were similar in the pediatric and adult patients, as were the rates of catheter function restoration."],"effective_time":"20260120","nursing_mothers":["Nursing Mothers It is not known whether Cathflo Activase is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cathflo Activase is administered to a nursing woman."],"clinical_studies":["CLINICAL STUDIES Three clinical studies were performed in patients with improperly functioning central venous access devices (CVADs). A placebo‑controlled, double‑blind, randomized trial (Trial 1) and a larger open‑label trial (Trial 2) investigated the use of Alteplase in predominately adult patients who had an indwelling CVAD for administration of chemotherapy, total parenteral nutrition, or long‑term administration of antibiotics or other medications. Both studies enrolled patients whose catheters were not functioning (defined as the inability to withdraw at least 3 mL of blood from the device) but had the ability to instill the necessary volume of study drug. Patients with hemodialysis catheters or a known mechanical occlusion were excluded from both studies. Also excluded were patients considered at high risk for bleeding or embolization (see PRECAUTIONS, Bleeding ), as well as patients who were younger than 2 years old or weighed less than 10 kg. Restoration of function was assessed by successful withdrawal of 3 mL of blood and infusion of 5 mL of saline through the catheter. Trial 1 tested the efficacy of a 2 mg/2 mL Alteplase dose in restoring function to occluded catheters in 150 patients with catheter occlusion up to 24 hours in duration. Patients were randomized to receive either Alteplase or placebo instilled into the lumen of the catheter, and catheter function was assessed at 120 minutes. Restoration of function was assessed by successful withdrawal of 3 mL of blood and infusion of 5 mL of saline through the catheter. All patients whose catheters did not meet these criteria were then administered Alteplase, until function was restored or each patient had received up to two active doses. After the initial dose of study agent, 51 (67%) of 76 patients randomized to Alteplase and 12 (16%) of 74 patients randomized to placebo had catheter function restored. This resulted in a treatment‑associated difference of 51% (95% CI is 37% to 64%). A total of 112 (88%) of 127 Alteplase‑treated patients had restored function after up to two doses. Trial 2 was an open‑label, single arm trial in 995 patients with catheter dysfunction and included patients with occlusions present for any duration. Patients were treated with Alteplase with up to two doses of 2 mg/2 mL (less for children who weighed less than 30 kg, see DOSAGE AND ADMINISTRATION ) instilled into the lumen of the catheter. Assessment for restoration of function was made at 30 minutes after each instillation. If function was not restored, catheter function was re‑assessed at 120 minutes. Thirty minutes after instillation of the first dose, 516 (52%) of 995 patients had restored catheter function. One hundred twenty minutes after the instillation of the first dose, 747 (75%) of 995 patients had restored catheter function. If function was not restored after the first dose, a second dose was administered. Two hundred nine patients received a second dose. Thirty minutes after instillation of the second dose, 70 (33%) of 209 patients had restored catheter function. One hundred twenty minutes after the instillation of the second dose, 97 (46%) of 209 patients had restored catheter function. A total of 844 (85%) of 995 patients had function restored after up to 2 doses. Across Trials 1 and 2, 796 (68%) of 1043 patients with occlusions present for less than 14 days had restored function after one dose, and 902 (88%) had function restored after up to two doses. Of 53 patients with occlusions present for longer than 14 days, 30 (57%) patients had function restored after a single dose, and a total of 38 patients (72%) had restored function after up to two doses. Three hundred forty-six patients who had successful treatment outcome were evaluated at 30 days after treatment. The incidence of recurrent catheter dysfunction within this period was 26%. Trial 3 was an open‑label, single‑arm trial in 310 patients between the ages of 2 weeks and 17 years. All patients had catheter dysfunction defined as the inability to withdraw blood (at least 3 mL for patients ≥ 10 kg or at least 1 mL for patients < 10 kg). Catheter dysfunction could be present for any duration. The indwelling CVADs (single-, double-, and triple‑lumen, and implanted ports) were used for administration of chemotherapy, blood products or fluid replacement, total parenteral nutrition, antibiotics, or other medications. Patients with hemodialysis catheters or known mechanical occlusions were excluded from the study, as were patients considered at high risk for bleeding or embolization. Patients were treated with up to two doses of Cathflo Activase instilled into the catheter lumen. For patients weighing ≥ 30 kg, the dose was 2 mg in 2 mL. For patients weighing < 30 kg, the dose was 110% of the estimated internal lumen volume, not to exceed 2 mg in 2 mL. Restoration of function was assessed at 30 and 120 minutes (if required) after administration of each dose. Restoration of function was defined as the ability to withdraw fluid (3 mL in patients ≥ 10 kg; 1 mL in patients < 10 kg) and infuse saline (5 mL in patients ≥ 10 kg; 3 mL in patients < 10 kg). The overall rate of catheter function restoration of 83% (257 of 310) was similar to that observed in Trial 2, as were the rates of function restoration at the intermediate assessments. The three trials had similar rates of catheter function restoration among the catheter types studied (single-, double-, and triple‑lumen, and implanted ports). No gender differences were observed in the rate of catheter function restoration. Results were similar across all age subgroups."],"adverse_reactions":["ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in Section PRECAUTIONS of the label: Bleeding Hypersensitivity In the clinical trials, the most serious adverse events reported after treatment were sepsis (see PRECAUTIONS, Infections ), gastrointestinal bleeding, and venous thrombosis. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Trials 1 and 2 The data described for Trials 1 and 2 reflect exposure to Cathflo Activase in 1122 patients, of whom 880 received a single dose and 242 received two sequential doses of Cathflo Activase. In the Cathflo Activase Trials 1 and 2, only limited, focused types of serious adverse events were recorded, including death, major hemorrhage, intracranial hemorrhage, pulmonary or arterial emboli, and other serious adverse events not thought to be attributed to underlying disease or concurrent illness. Major hemorrhage was defined as severe blood loss ( > 5 mL/kg), blood loss requiring transfusion, or blood loss causing hypotension. Non‑serious adverse events and serious events thought to be due to underlying disease or concurrent illness were not recorded. Patients were observed for serious adverse events until catheter function was deemed to be restored or for a maximum of 4 or 6 hours depending on study. For most patients the observation period was 30 minutes to 2 hours. Spontaneously reported deaths and serious adverse events that were not thought to be related to the patient's underlying disease were also recorded during the 30 days following treatment. Four catheter-related sepsis events occurred from 15 minutes to 1 day after treatment with Alteplase, and a fifth sepsis event occurred on Day 3 after Alteplase treatment. All 5 patients had positive catheter or peripheral blood cultures within 24 hours after symptom onset. Three patients had a major hemorrhage from a gastrointestinal source from 2 to 3 days after Alteplase treatment. One case of injection site hemorrhage was observed at 4 hours after treatment in a patient with pre-existing thrombocytopenia. These events may have been related to underlying disease and treatments for malignancy, but a contribution to occurrence of the events from Alteplase cannot be ruled out. There were no reports of intracranial hemorrhage. Three cases of subclavian and upper extremity deep venous thrombosis were reported 3 to 7 days after treatment. These events may have been related to underlying disease or to the long-term presence of an indwelling catheter, but a contribution to occurrence of the events from Alteplase treatment cannot be ruled out. There were no reports of pulmonary emboli. There were no gender-related differences observed in the rates of adverse reactions. Adverse reactions profiles were similar across all age subgroups. Trial 3 In Trial 3 all serious adverse events were recorded with a specific interest in intracranial hemorrhage, major hemorrhage, thrombosis, embolic events, sepsis and catheter related complications. Major hemorrhage was defined as severe blood loss ( > 5 mL/kg), blood loss requiring transfusion, or blood loss causing hypotension. Non-serious adverse events were not recorded. Patients were observed until catheter function was deemed to be restored or for a maximum of 4 hours after the first dose. Additionally, serious adverse events were elicited from patients at 48 hours (up to 96 hours) following completion of treatment. No pediatric patients in Trial 3 experienced an intracranial hemorrhage, major hemorrhage, thrombosis, or an embolic event. Three cases of sepsis occurred 2 to 44 hours after treatment with Cathflo Activase. All of these patients had evidence of infection prior to administration of Cathflo Activase. An additional patient developed fever and lethargy within one day of Cathflo Activase administration, which required outpatient intravenous antibiotics. In one subject, the lumen of the catheter, placed 2 years previously, ruptured with infusion of the study drug. There were no gender-related differences observed in the rates of adverse reactions. Adverse reactions profiles were similar across all age groups."],"contraindications":["CONTRAINDICATIONS Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation (see DESCRIPTION )."],"drug_interactions":["Drug Interactions The interaction of Cathflo Activase with other drugs has not been formally studied. Concomitant use of drugs affecting coagulation and/or platelet function has not been studied."],"general_precautions":["General Catheter dysfunction may be caused by a variety of conditions other than thrombus formation, such as catheter malposition, mechanical failure, constriction by a suture, and lipid deposits or drug precipitates within the catheter lumen. These types of conditions should be considered before treatment with Cathflo Activase. Because of the risk of damage to the vascular wall or collapse of soft‑walled catheters, vigorous suction should not be applied during attempts to determine catheter occlusion. Excessive pressure should be avoided when Cathflo Activase is instilled into the catheter. Such force could cause rupture of the catheter or expulsion of the clot into the circulation."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Alteplase is an enzyme (serine protease) that has the property of fibrin-enhanced conversion of plasminogen to plasmin. It produces limited conversion of plasminogen in the absence of fibrin. Alteplase binds to fibrin in a thrombus and converts the entrapped plasminogen to plasmin, thereby initiating local fibrinolysis (1). In patients with acute myocardial infarction administered 100 mg of Activase as an accelerated intravenous infusion over 90 minutes, plasma clearance occurred with an initial half‑life of less than 5 minutes and a terminal half‑life of 72 minutes. Clearance is mediated primarily by the liver (2). When Cathflo Activase is administered for restoration of function to central venous access devices according to the instructions in DOSAGE AND ADMINISTRATION, circulating plasma levels of Alteplase are not expected to reach pharmacologic concentrations. If a 2 mg dose of Alteplase were administered by bolus injection directly into the systemic circulation (rather than instilled into the catheter), the concentration of circulating Alteplase would be expected to return to endogenous circulating levels of 5–10 ng/mL within 30 minutes (1)."],"indications_and_usage":["INDICATIONS AND USAGE Cathflo ® Activase ® (Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood."],"spl_unclassified_section":["Powder for reconstitution for use in central venous access devices","Cathflo ® Activase ® (Alteplase) Manufactured by: Genentech, Inc. A Member of the Roche Group 1 DNA Way South San Francisco, CA 94080-4990 US License No. 1048 FDA Approval Date January 2005 Revised: 02/2019 Cathflo® Activase® is a trademark of Genentech, Inc. © 2019 Genentech, Inc. Representative sample of labeling (see the HOW SUPPLIED section for complete listing):"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Cathflo ® Activase ® (Alteplase) is for instillation into the dysfunctional catheter at a concentration of 1 mg/mL. • Patients weighing ≥30 kg: 2 mg in 2 mL • Patients weighing <30 kg: 110% of the internal lumen volume of the catheter, not to exceed 2 mg in 2 mL If catheter function is not restored at 120 minutes after 1 dose of Cathflo Activase, a second dose may be instilled (see Instructions for Administration ). There is no efficacy or safety information on dosing in excess of 2 mg per dose for this indication. Studies have not been performed with administration of total doses greater than 4 mg (two 2‑mg doses). Instructions for Administration Preparation of Solution Reconstitute Cathflo Activase to a final concentration of 1 mg/mL: Aseptically withdraw 2.2 mL of Sterile Water for Injection, USP (diluent is not provided). Do not use Bacteriostatic Water for Injection. Inject the 2.2 mL of Sterile Water for Injection, USP, into the Cathflo Activase vial, directing the diluent stream into the powder. Slight foaming is not unusual; let the vial stand undisturbed to allow large bubbles to dissipate. Mix by gently swirling until the contents are completely dissolved. Complete dissolution should occur within 3 minutes. DO NOT SHAKE. The reconstituted preparation results in a colorless to pale yellow transparent solution containing 1 mg/mL Cathflo Activase at a pH of approximately 7.3. Cathflo Activase contains no antibacterial preservatives and should be reconstituted immediately before use. The solution may be used for intracatheter instillation within 8 hours following reconstitution when stored at 2–30°C (36–86°F). No other medication should be added to solutions containing Cathflo Activase. Instillation of Solution into the Catheter Inspect the product prior to administration for foreign matter and discoloration. Withdraw 2 mL (2 mg) of solution from the reconstituted vial. Instill the appropriate dose of Cathflo Activase (see DOSAGE AND ADMINISTRATION ) into the occluded catheter. After 30 minutes of dwell time, assess catheter function by attempting to aspirate blood. If the catheter is functional, go to Step 7. If the catheter is not functional, go to Step 5. After 120 minutes of dwell time, assess catheter function by attempting to aspirate blood and catheter contents. If the catheter is functional, go to Step 7. If the catheter is not functional, go to Step 6. If catheter function is not restored after one dose of Cathflo Activase, a second dose of equal amount may be instilled. Repeat the procedure beginning with Step 1 under Preparation of Solution. If catheter function has been restored, aspirate 4–5 mL of blood in patients ≥10 kg or 3 mL in patients <10 kg to remove Cathflo Activase and residual clot, and gently irrigate the catheter with 0.9% Sodium Chloride Injection, USP. Any unused solution should be discarded . Stability and Storage Store lyophilized Cathflo Activase at refrigerated temperature (2–8°C/36–46°F). Do not use beyond the expiration date on the vial. Protect the lyophilized material during extended storage from excessive exposure to light."],"spl_product_data_elements":["Cathflo Activase Alteplase ALTEPLASE ALTEPLASE ARGININE POLYSORBATE 80 PHOSPHORIC ACID"],"spl_unclassified_section_table":["<table width=\"75%\"><col width=\"50%\" align=\"left\" valign=\"top\"/><col width=\"50%\" align=\"right\" valign=\"top\"/><tbody><tr><td colspan=\"2\"><paragraph><content styleCode=\"bold\">Cathflo<sup>&#xAE;</sup> Activase<sup>&#xAE;</sup> (Alteplase)</content></paragraph></td></tr><tr><td align=\"left\" valign=\"top\"><paragraph>Manufactured by: <content styleCode=\"bold\">Genentech, Inc.</content> A Member of the Roche Group 1 DNA Way South San Francisco, CA 94080-4990 US License No. 1048</paragraph></td><td align=\"right\" valign=\"top\"><paragraph> FDA Approval Date January 2005 Revised: 02/2019 Cathflo&#xAE; Activase&#xAE; is a trademark of Genentech, Inc. <sup>&#xA9;</sup>2019 Genentech, Inc.</paragraph></td></tr></tbody></table>"],"dosage_and_administration_table":["<table width=\"68%\"><col width=\"33%\"/><col width=\"35%\"/><tbody><tr><td><paragraph>&#x2022; Patients weighing &#x2265;30 kg:</paragraph></td><td>2 mg in 2 mL</td></tr><tr><td><paragraph>&#x2022; Patients weighing &lt;30 kg:</paragraph></td><td>110% of the internal lumen volume of the catheter, not to exceed 2 mg in 2 mL</td></tr></tbody></table>"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 2 mg Vial Carton NDC 50242-041-64 US License No.: 1048 cathflo ® activase ® (ALTEPLASE) 2 mg For Use in Central Venous Access Devices Rx only KEEP REFRIGERATED 10165659 Genentech Principal Display Panel - 2 mg Vial Carton"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interactions Potential interactions between Cathflo Activase and laboratory tests have not been studied."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Long‑term studies in animals have not been performed to evaluate the carcinogenic potential or the effect on fertility. Short-term studies that evaluated tumorigenicity of Alteplase and effect on tumor metastases were negative in rodents. Studies to determine mutagenicity (Ames test) and chromosomal aberration assays in human lymphocytes were negative at all concentrations tested. Cytotoxicity, as reflected by a decrease in mitotic index, was evidenced only after prolonged exposure at high concentrations exceeding those expected to be achieved with Cathflo Activase."]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Plasminogen","category":"target"},{"label":"PLG","category":"gene"},{"label":"B01AD02","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Acute myocardial infarction","category":"indication"},{"label":"Ischemic stroke","category":"indication"},{"label":"Pulmonary embolism","category":"indication"},{"label":"Genentech","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Fibrinolytic Agents","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":3273.634,"date":"","count":1113,"signal":"No adverse event","source":"DrugCentral FAERS","actionTaken":"Reported 1,113 times (LLR=3274)"},{"llr":2811.913,"date":"","count":517,"signal":"Haemorrhagic transformation stroke","source":"DrugCentral FAERS","actionTaken":"Reported 517 times (LLR=2812)"},{"llr":2440.942,"date":"","count":719,"signal":"Haemorrhage intracranial","source":"DrugCentral FAERS","actionTaken":"Reported 719 times (LLR=2441)"},{"llr":2292.461,"date":"","count":821,"signal":"Cerebral haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 821 times (LLR=2292)"},{"llr":1486.706,"date":"","count":642,"signal":"Angioedema","source":"DrugCentral FAERS","actionTaken":"Reported 642 times (LLR=1487)"},{"llr":1214.378,"date":"","count":1307,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 1,307 times (LLR=1214)"},{"llr":925.572,"date":"","count":519,"signal":"Haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 519 times (LLR=926)"},{"llr":873.518,"date":"","count":201,"signal":"Intercepted medication error","source":"DrugCentral FAERS","actionTaken":"Reported 201 times (LLR=874)"},{"llr":775.874,"date":"","count":107,"signal":"Modified Rankin score increased","source":"DrugCentral FAERS","actionTaken":"Reported 107 times (LLR=776)"},{"llr":694.034,"date":"","count":141,"signal":"Intercepted product storage error","source":"DrugCentral FAERS","actionTaken":"Reported 141 times (LLR=694)"},{"llr":517.944,"date":"","count":228,"signal":"Product storage error","source":"DrugCentral FAERS","actionTaken":"Reported 228 times (LLR=518)"},{"llr":448.151,"date":"","count":133,"signal":"Neurological decompensation","source":"DrugCentral FAERS","actionTaken":"Reported 133 times (LLR=448)"},{"llr":438.342,"date":"","count":142,"signal":"Cerebral haematoma","source":"DrugCentral FAERS","actionTaken":"Reported 142 times (LLR=438)"},{"llr":360.201,"date":"","count":77,"signal":"Haemorrhagic infarction","source":"DrugCentral FAERS","actionTaken":"Reported 77 times (LLR=360)"},{"llr":339.105,"date":"","count":201,"signal":"Cerebral infarction","source":"DrugCentral FAERS","actionTaken":"Reported 201 times (LLR=339)"}],"drugInteractions":[{"drug":"drugs affecting coagulation and/or platelet function","severity":"major","mechanism":"unknown (not studied)","management":"monitor for signs of bleeding; use caution","clinicalEffect":"potential increased risk of bleeding"}],"commonSideEffects":[{"effect":"Major hemorrhage","drugRate":"reported","severity":"serious"},{"effect":"Sepsis","drugRate":"reported","severity":"serious"},{"effect":"Venous thrombosis","drugRate":"reported","severity":"serious"},{"effect":"Pulmonary or arterial emboli","drugRate":"reported","severity":"serious"},{"effect":"Intracranial hemorrhage","drugRate":"reported","severity":"serious"},{"effect":"Gastrointestinal bleeding","drugRate":"reported","severity":"serious"},{"effect":"Death","drugRate":"reported","severity":"serious"},{"effect":"Injection site hemorrhage","drugRate":"reported","severity":"serious"},{"effect":"Subclavian and upper extremity deep venous thrombosis","drugRate":"reported","severity":"serious"},{"effect":"Fever","drugRate":"reported","severity":"mild"},{"effect":"Lethargy","drugRate":"reported","severity":"mild"},{"effect":"Hypotension","drugRate":"reported","severity":"serious"},{"effect":"Blood loss causing hypotension","drugRate":"reported","severity":"serious"},{"effect":"Blood loss requiring transfusion","drugRate":"reported","severity":"serious"},{"effect":"Severe blood loss","drugRate":"reported","severity":"serious"}],"contraindications":["Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation."],"specialPopulations":{"Pregnancy":"Alteplase has been shown to have an embryocidal effect due to an increased postimplantation loss rate in rabbits when administered intravenously during organogenesis at dose (3 mg/kg) approximately 50 times human exposure (based on AUC) at the dose for restoration of function to occluded CVADs. No maternal or fetal toxicity was evident at dose (1 mg/kg) approximately 16 times human exposure at the dose for restoration of function to occluded CVADs.","Geriatric use":"In 312 patients enrolled who were age 65 years and over, no incidents of intracranial hemorrhage (ICH), embolic events, or major bleeding events were observed. One hundred three of these patients were age 75 years and over, and 12 were age 85 years and over. The effect of Alteplase on common age-related comorbidities has not been studied. In general, caution should be used in geriatric patients with conditions known to increase the risk of bleeding (see PRECAUTIONS, Bleeding).","Paediatric use":"Rates of serious adverse events were similar in the pediatric and adult patients, as were the rates of catheter function restoration."}},"trials":[],"aliases":[],"company":"Roche","patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:31:06.765227","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ALTEPLASE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:30:38.226307+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Alteplase","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:30:45.686345+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:30:43.760350+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALTEPLASE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:30:44.630736+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:30:37.116765+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:31:03.218215+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:30:37.116794+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tissue-type plasminogen activator exogenous protein","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:30:45.686303+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:30:57.563138+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201593/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:30:45.337978+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in Section PRECAUTIONS of the label: Bleeding Hypersensitivity In the clinical trials, the most serious adverse events reported after treatment were sepsis (see PRECAUTIONS, Infections ), gastrointestinal bleeding, and venous thrombosis. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the ","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:30:49.546857+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:30:52.464306+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA103172","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:30:37.116797+00:00"}},"allNames":"activase","offLabel":[],"synonyms":["alteplase","activase","alteplase (genetical recombination)"],"timeline":[{"date":"1996-06-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Genentech)"}],"aiSummary":"Activase (Alteplase) is a recombinant tissue plasminogen activator (tPA) developed by Genentech, used to treat acute myocardial infarction, ischemic stroke, and pulmonary embolism. It works by binding to plasminogen and converting it into plasmin, which then breaks down blood clots. As a patented product, its commercial status is proprietary, and it requires careful administration due to potential bleeding risks. Key safety considerations include the risk of intracranial hemorrhage and the need for close monitoring. Activase has been FDA-approved since 1996.","brandName":"Activase","ecosystem":[{"indication":"Acute myocardial infarction","otherDrugs":[{"name":"reteplase","slug":"reteplase","company":"Ekr Therap"},{"name":"tenecteplase","slug":"tenecteplase","company":"Genentech"}],"globalPrevalence":null},{"indication":"Ischemic stroke","otherDrugs":[{"name":"edaravone","slug":"edaravone","company":"Mitsubishi Tanabe Pharma Development America Inc"},{"name":"edoxaban","slug":"edoxaban","company":"Daiichi Sankyo"}],"globalPrevalence":null},{"indication":"Pulmonary embolism","otherDrugs":[{"name":"bemiparin","slug":"bemiparin","company":"Pfizer Inc"},{"name":"dabigatran etexilate","slug":"dabigatran-etexilate","company":"Boehringer Ingelheim"},{"name":"edoxaban","slug":"edoxaban","company":"Daiichi Sankyo"},{"name":"enoxaparin sodium","slug":"enoxaparin-sodium","company":"Sanofi Aventis Us"}],"globalPrevalence":null}],"mechanism":{"target":"Plasminogen","novelty":"Follow-on","targets":[{"gene":"PLG","source":"DrugCentral","target":"Plasminogen","protein":"Plasminogen"}],"modality":"Biologic","explanation":"","oneSentence":"","technicalDetail":"Activase (Alteplase) is a recombinant human tissue plasminogen activator (tPA) that specifically binds to plasminogen, converting it into plasmin through a proteolytic reaction, ultimately leading to fibrinolysis and clot dissolution."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Alteplase","title":"Alteplase","extract":"Alteplase, sold under the brand name Activase among others, is a biosynthetic form of human tissue-type plasminogen activator (t-PA). It is a thrombolytic medication used to treat acute ischemic stroke, acute ST-elevation myocardial infarction, pulmonary embolism associated with low blood pressure, and blocked central venous catheter. Alteplase is given by injection into a vein or artery. Alteplase is the same as the normal human plasminogen activator produced in vascular endothelial cells and is synthesized via recombinant DNA technology in Chinese hamster ovary cells (CHO). Alteplase causes the breakdown of a clot by inducing fibrinolysis.","wiki_history":"== History ==\nIn 1995, a study by the National Institute of Neurological Disorders and Stroke showed the effectiveness of administering intravenous alteplase to treat ischemic stroke. This sparked a medical paradigm shift as it redesigned stroke treatment in the emergency department to allow for timely assessment and therapy for ischemic stroke patients.","wiki_society_and_culture":"==Society and culture==\nAlteplase was added to the World Health Organization's List of Essential Medicines in 2019, for use in ischemic stroke.\n\n=== Legal status ===\nIn May 1987, the US Food and Drug Administration (FDA) requested additional data for the drug rather than approve it outright, causing Genentech stock prices to fall by nearly one quarter. The decision was described as a surprise to the company as well as many cardiologists and regulators, and it generated significant criticism of the FDA.\n\nAfter results from two additional trials were obtained, This was just seven years after the first efforts were made to produce recombinant t-PA, making it one of the fastest drug developments in history. However, alteplase continues to be cost-effective. Activase,\n\n=== Controversies ===\nAlteplase is underused in low- and middle-income countries. This may be due to its high cost and the fact that it is often not covered by health insurance.\n\nThere is a sex difference in the use of intravenous tissue plasminogen activator, as it is less likely to be used for women with acute ischemic stroke than men. However, this difference has been improving since 2008."},"commercial":{"launchDate":"1996","_launchSource":"DrugCentral (FDA 1996-06-18, GENENTECH)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5141","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ALTEPLASE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALTEPLASE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Alteplase","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:39:06.685036","_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:31:03.358816+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"urokinase","drugSlug":"urokinase","fdaApproval":"","relationship":"same-class"},{"drugName":"reteplase","drugSlug":"reteplase","fdaApproval":"1996-10-30","relationship":"same-class"},{"drugName":"tenecteplase","drugSlug":"tenecteplase","fdaApproval":"2000-06-02","relationship":"same-class"}],"genericName":"alteplase","indications":{"approved":[{"id":"alteplase-restoration-of-function-to-cen","name":"Restoration of function to central venous access devices","dosing":null,"approvals":[],"diseaseId":"","eligibility":null,"pivotalTrial":null,"restrictions":[],"patientPopulation":null,"diagnosticRequired":null,"brandNameForIndication":"Activase"}],"offLabel":[],"pipeline":[]},"_fixedFields":["modality→Biologic"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"urokinase","brandName":"urokinase","genericName":"urokinase","approvalYear":"","relationship":"same-class"},{"drugId":"reteplase","brandName":"reteplase","genericName":"reteplase","approvalYear":"1996","relationship":"same-class"},{"drugId":"tenecteplase","brandName":"tenecteplase","genericName":"tenecteplase","approvalYear":"2000","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07471256","phase":"PHASE3","title":"Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2026-03-31","conditions":["Intracerebral Hemorrhage Lobar"],"enrollment":636,"completionDate":"2028-12-31"},{"nctId":"NCT07253181","phase":"PHASE3","title":"Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-06","conditions":["Acute Ischemic Stroke","Large Vessel Occlusion","Transportation of Patients"],"enrollment":572,"completionDate":"2028-03-30"},{"nctId":"NCT07476898","phase":"PHASE3","title":"Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03-01","conditions":["Stroke"],"enrollment":864,"completionDate":"2028-08-01"},{"nctId":"NCT07361302","phase":"PHASE3","title":"A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-02-17","conditions":["Acute Ischemic Stroke"],"enrollment":1325,"completionDate":"2027-10-02"},{"nctId":"NCT07475949","phase":"PHASE3","title":"Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-04","conditions":["Acute Ischemic Stroke","Tenecteplase"],"enrollment":352,"completionDate":"2028-12"},{"nctId":"NCT07475936","phase":"","title":"Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-04","conditions":["Acute Ischemic Stroke","Tenecteplase"],"enrollment":392,"completionDate":"2027-12"},{"nctId":"NCT07471282","phase":"PHASE3","title":"Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy","status":"NOT_YET_RECRUITING","sponsor":"Chuansheng Zhao","startDate":"2026-03-01","conditions":["Stroke"],"enrollment":344,"completionDate":"2029-03-31"},{"nctId":"NCT05491356","phase":"PHASE4","title":"Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2023-05-11","conditions":["Hematoma, Subdural","Fibrinolytic; Hemorrhage"],"enrollment":40,"completionDate":"2024-05-30"},{"nctId":"NCT02860260","phase":"NA","title":"Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2011-02","conditions":["Ischemic Stroke"],"enrollment":50,"completionDate":""},{"nctId":"NCT07432373","phase":"","title":"Intrapleural Alteplase-Tyloxapol vs Intrapleural Alteplase-DNase in Pleural Infection","status":"NOT_YET_RECRUITING","sponsor":"National University of Malaysia","startDate":"2026-04-01","conditions":["Pleural Infection"],"enrollment":80,"completionDate":"2028-07-01"},{"nctId":"NCT04667078","phase":"PHASE3","title":"REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2022-03-02","conditions":["Acute Ischemia"],"enrollment":368,"completionDate":"2030-09-01"},{"nctId":"NCT06018181","phase":"","title":"Outcomes After Intravenous Alteplase / Tenecteplase With or Without Shuxuetong Injection in Routine Clinical Practice","status":"COMPLETED","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2023-09-28","conditions":["Ischemic Stroke, Acute"],"enrollment":2408,"completionDate":"2025-09-03"},{"nctId":"NCT05903417","phase":"NA","title":"Pleural Irrigation With Normal Saline Versus Intrapleural Fibrinolytic","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2023-07-10","conditions":["Pleural Infection"],"enrollment":40,"completionDate":"2025-10-14"},{"nctId":"NCT06241677","phase":"NA","title":"Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-04-15","conditions":["CVA (Cerebrovascular Accident)"],"enrollment":260,"completionDate":"2029-03-31"},{"nctId":"NCT05983757","phase":"NA","title":"Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe","status":"RECRUITING","sponsor":"Raul Nogueira","startDate":"2024-04-02","conditions":["Ischemic Stroke"],"enrollment":584,"completionDate":"2027-11"},{"nctId":"NCT06427538","phase":"NA","title":"Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2024-06-21","conditions":["Empyema, Pleural","Pleural Infection"],"enrollment":96,"completionDate":"2026-12-30"},{"nctId":"NCT07375953","phase":"PHASE2","title":"Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK)","status":"NOT_YET_RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-03-01","conditions":["Ischemic Stroke"],"enrollment":120,"completionDate":"2027-12-30"},{"nctId":"NCT04918719","phase":"PHASE2","title":"Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2023-11-02","conditions":["Acute Ischemic Stroke"],"enrollment":4,"completionDate":"2024-09-17"},{"nctId":"NCT07375966","phase":"PHASE2","title":"Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours of Onset With Tenecteplase (RITIS-TNK2)","status":"NOT_YET_RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-03-01","conditions":["Ischemic Stroke"],"enrollment":198,"completionDate":"2026-12-30"},{"nctId":"NCT07419997","phase":"","title":"A Multicenter, Retrospective, Observational Cohort Study on Intravenous Thrombolysis Beyond the Time Window for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-12-29","conditions":["Stroke"],"enrollment":2600,"completionDate":"2026-12-29"},{"nctId":"NCT05701956","phase":"PHASE3","title":"Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion","status":"COMPLETED","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2023-03-16","conditions":["Basilar Artery Occlusion","Acute Cerebrovascular Accident","Stroke Due to Basilar Artery Occlusion"],"enrollment":330,"completionDate":"2025-05-04"},{"nctId":"NCT07411079","phase":"","title":"Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator for Intracerebral Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2026-02","conditions":["Intracerebral Hemorrhage","Hemorrhagic Risk Conditions","Bleeding Disorders"],"enrollment":1126,"completionDate":"2026-02"},{"nctId":"NCT05499832","phase":"PHASE3","title":"Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-21","conditions":["Ischemic Stroke"],"enrollment":156,"completionDate":"2025-10-09"},{"nctId":"NCT02557451","phase":"NA","title":"Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2016-04-28","conditions":["Subretinal Haematoma Linked to AMD"],"enrollment":91,"completionDate":""},{"nctId":"NCT04663750","phase":"PHASE3","title":"Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).","status":"RECRUITING","sponsor":"King's College Hospital NHS Trust","startDate":"2021-04-16","conditions":["Eye Diseases","Macular Degeneration, Wet","Sub-Macular Hemorrhage"],"enrollment":210,"completionDate":"2028-12"},{"nctId":"NCT07111559","phase":"PHASE4","title":"Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial","status":"RECRUITING","sponsor":"Nippon Medical School","startDate":"2025-08-01","conditions":["Lacunar Stroke","Stroke","Ischemic Stroke"],"enrollment":500,"completionDate":"2029-03-31"},{"nctId":"NCT07374978","phase":"NA","title":"Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-07-01","conditions":["Pulmonary Embolism Subacute Massive","Thrombolytic Therapy"],"enrollment":100,"completionDate":"2025-07-01"},{"nctId":"NCT07360717","phase":"NA","title":"To Compare the Efficacy & Safety of Ultra-Slow (24 hr) Low Dose (25 mg) Infusion of Alteplase Over Slow (24hr) Infusion of Streptokinase in Mechanical Prosthetic Valve Thrombosis","status":"COMPLETED","sponsor":"U. N. Mehta Institute of Cardiology and Research Center","startDate":"2024-11-01","conditions":["Thrombolysed"],"enrollment":100,"completionDate":"2025-12-31"},{"nctId":"NCT06658197","phase":"PHASE3","title":"Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-12-25","conditions":["Stroke, Ischemic","Stroke, Acute","Thrombosis, Brain","Drug Effect"],"enrollment":850,"completionDate":"2027-06-01"},{"nctId":"NCT06310018","phase":"","title":"Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE","status":"SUSPENDED","sponsor":"Brigham and Women's Hospital","startDate":"2027-01-01","conditions":["Pulmonary Embolism","Right Ventricular Dysfunction","Right Ventricular Failure"],"enrollment":60,"completionDate":"2028-12-31"},{"nctId":"NCT07302854","phase":"PHASE2,PHASE3","title":"Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion","status":"RECRUITING","sponsor":"Xiang Luo","startDate":"2025-12-30","conditions":["Acute Ischemic Stroke","Medium Vessel Occlusion"],"enrollment":382,"completionDate":"2028-12"},{"nctId":"NCT07003646","phase":"","title":"Reperfusion Treatment in Acute Pulmonary Embolism","status":"RECRUITING","sponsor":"Sahlgrenska University Hospital","startDate":"2025-04-01","conditions":["Pulmonary Embolism"],"enrollment":220,"completionDate":"2029-05-01"},{"nctId":"NCT06949228","phase":"PHASE2,PHASE3","title":"Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial","status":"RECRUITING","sponsor":"ProMedica Health System","startDate":"2025-07-30","conditions":["Ischemic Stroke","Acute Disease"],"enrollment":132,"completionDate":"2028-05-30"},{"nctId":"NCT07347626","phase":"PHASE3","title":"Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis","status":"NOT_YET_RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2026-03-01","conditions":["Acute Ischemic Stroke"],"enrollment":786,"completionDate":"2029-12-31"},{"nctId":"NCT07271342","phase":"","title":"Observational RegIstry of Effectiveness and Safety of teNecTeplase in reAl worLd Settings in China","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-11-30","conditions":["Stroke"],"enrollment":10000,"completionDate":"2029-06-30"},{"nctId":"NCT07318948","phase":"NA","title":"BALANCE Trial Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632","status":"NOT_YET_RECRUITING","sponsor":"Bo Wu","startDate":"2026-01-01","conditions":["Acute Ischemic Stroke"],"enrollment":1600,"completionDate":"2028-09-30"},{"nctId":"NCT00412867","phase":"PHASE4","title":"Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2006-12","conditions":["Stroke"],"enrollment":58,"completionDate":"2008-06"},{"nctId":"NCT05766124","phase":"PHASE2,PHASE3","title":"Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE)","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-11-01","conditions":["Pleural Infection"],"enrollment":30,"completionDate":"2028-06-30"},{"nctId":"NCT00147316","phase":"PHASE3","title":"Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2002-04","conditions":["Cerebral Infarction","Brain Ischemia"],"enrollment":103,"completionDate":"2003-09"},{"nctId":"NCT06210633","phase":"","title":"Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke","status":"RECRUITING","sponsor":"Zhongming Qiu","startDate":"2024-01-20","conditions":["Acute Ischemic Stroke (AIS)","Acute Ischemic Stroke From Large Vessel Occlusion"],"enrollment":1000,"completionDate":"2026-03-31"},{"nctId":"NCT04434768","phase":"PHASE1","title":"Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ever Supreme Bio Technology Co., Ltd.","startDate":"2020-12-02","conditions":["Acute Stroke"],"enrollment":10,"completionDate":"2026-02-28"},{"nctId":"NCT05728333","phase":"PHASE2,PHASE3","title":"Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke","status":"RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2023-11-28","conditions":["Stroke, Acute Ischemic"],"enrollment":800,"completionDate":"2026-07-31"},{"nctId":"NCT06184321","phase":"EARLY_PHASE1","title":"Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-17","conditions":["Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm"],"enrollment":30,"completionDate":"2027-02-02"},{"nctId":"NCT07092709","phase":"PHASE3","title":"Tenecteplase for Intravenous Stroke Thrombolysis in Recent DOAC Users","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-08-14","conditions":["Acute Ischemic Stroke"],"enrollment":912,"completionDate":"2028-12-31"},{"nctId":"NCT07201688","phase":"PHASE3","title":"Phase III Clinical Trial of rhTNK-tPA in Treating Acute Ischemic Stroke With Extended Time Window.","status":"RECRUITING","sponsor":"CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2025-11-30","conditions":["Acute Ischemic Stroke"],"enrollment":890,"completionDate":"2027-09-30"},{"nctId":"NCT05752916","phase":"PHASE4","title":"Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-06-02","conditions":["Acute Ischemic Stroke"],"enrollment":570,"completionDate":"2025-10-28"},{"nctId":"NCT07208097","phase":"NA","title":"Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-10-25","conditions":["Intracerebral Haemorrhage","Minimally Invasive Treatment"],"enrollment":768,"completionDate":"2028-06-30"},{"nctId":"NCT05363397","phase":"PHASE2","title":"Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke","status":"RECRUITING","sponsor":"The Florey Institute of Neuroscience and Mental Health","startDate":"2023-09-27","conditions":["Acute Ischemic Stroke"],"enrollment":80,"completionDate":"2026-05-01"},{"nctId":"NCT06221371","phase":"PHASE3","title":"Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-01-25","conditions":["Ischemic Stroke, Acute","Thrombolysis","Endovascular Treatment"],"enrollment":391,"completionDate":"2025-10-13"},{"nctId":"NCT06196320","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-01-24","conditions":["Ischemic Stroke, Acute"],"enrollment":452,"completionDate":"2025-09-22"},{"nctId":"NCT05631847","phase":"NA","title":"Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke","status":"COMPLETED","sponsor":"Sichuan Academy of Medical Sciences","startDate":"2023-04-17","conditions":["Acute Ischemic Stroke","Basilar Artery Occlusion","Thrombosis","Alteplase","Endovascular Treatment"],"enrollment":345,"completionDate":"2025-08-28"},{"nctId":"NCT07227740","phase":"","title":"Testosterone Deficiency and Endothelial Dysfunction After Spinal Cord Injury","status":"RECRUITING","sponsor":"Craig Hospital","startDate":"2025-07-15","conditions":["Spinal Cord Injuries","Endothelial Dysfunction","Testosterone Deficiency"],"enrollment":48,"completionDate":"2028-07-14"},{"nctId":"NCT07047014","phase":"PHASE3","title":"Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-07-30","conditions":["Stroke, Ischemic","Medium Vessel Occlusions"],"enrollment":596,"completionDate":"2027-06-30"},{"nctId":"NCT06954155","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-05-30","conditions":["Stroke"],"enrollment":330,"completionDate":"2027-05-30"},{"nctId":"NCT07162363","phase":"PHASE2,PHASE3","title":"Synergistic Minimally Invasive Surgery and Deferoxamine in ICH","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2026-03-01","conditions":["Intracerebral Hemorrhage","ICH - Intracerebral Hemorrhage"],"enrollment":240,"completionDate":"2028-12-30"},{"nctId":"NCT04095676","phase":"NA","title":"VATS Surgery Compared to Drainage in the Treatment of Pleural Empyema","status":"RECRUITING","sponsor":"Thomas Decker Christensen","startDate":"2022-10-30","conditions":["Pleural Empyema"],"enrollment":184,"completionDate":"2028-10-30"},{"nctId":"NCT04526951","phase":"PHASE3","title":"TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2020-10-30","conditions":["Central Retinal Artery Occlusion"],"enrollment":81,"completionDate":"2025-06-20"},{"nctId":"NCT03335839","phase":"PHASE3","title":"Adjunctive, Low-dose tPA in Primary PCI for STEMI","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2018-04-01","conditions":["Myocardial Infarction","Percutaneous Coronary Intervention"],"enrollment":210,"completionDate":"2025-02-12"},{"nctId":"NCT06320431","phase":"PHASE3","title":"ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2024-09-26","conditions":["Acute Ischemic Stroke AIS","Stroke Acute","Stroke, Acute, Stroke Ischemic"],"enrollment":4000,"completionDate":"2030-12-31"},{"nctId":"NCT05797792","phase":"PHASE3","title":"CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Clinic of Barcelona","startDate":"2023-11-18","conditions":["Stroke, Acute Ischemic","Stroke, Acute"],"enrollment":440,"completionDate":"2025-11-14"},{"nctId":"NCT07168278","phase":"PHASE3","title":"Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2025-11-01","conditions":["Acute Ischemic Stroke","Large Vessel Occlusion","Tenecteplase","Thrombolysis"],"enrollment":794,"completionDate":"2028-05-31"},{"nctId":"NCT07095361","phase":"PHASE4","title":"Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-09","conditions":["Pleural Infection Bacterial","Pleural Infections","Pleural Infections and Inflammations","Empyema, Pleural","Empyema","Complicated Pleural Effusion/ Empyema","Pleural Effusion Associated With Pulmonary Infection","Pleural Effusion"],"enrollment":270,"completionDate":"2027-06"},{"nctId":"NCT06337175","phase":"PHASE4","title":"Predictors of Post-alteplase Hemorrhagic Transformation of Brain Infarction","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2021-06-01","conditions":["Ischemic Stroke","Alteplase Adverse Reaction"],"enrollment":600,"completionDate":"2024-04-30"},{"nctId":"NCT06878066","phase":"PHASE3","title":"Thrombolysis in Factor Xa-inhibitors Trial","status":"RECRUITING","sponsor":"Guri Hagberg","startDate":"2025-03-14","conditions":["Stroke","Stroke (in Patients With Atrial Fibrillation)","Ischemic Stroke","Acute Ischemic Stroke","Anticoagulant Therapy","Factor Xa Inhibitor","Intracranial Hemorrhages","Hemorrhagic Transformation Due to Acute Stroke","Bleeding in the Brain"],"enrollment":300,"completionDate":"2037-12-31"},{"nctId":"NCT07146360","phase":"PHASE3","title":"Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"AO GENERIUM","startDate":"2014-05-25","conditions":["Myocardial Infarction (MI)"],"enrollment":180,"completionDate":"2017-12-11"},{"nctId":"NCT06010628","phase":"PHASE4","title":"Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2024-02-01","conditions":["Stroke, Ischemic"],"enrollment":1440,"completionDate":"2026-12-15"},{"nctId":"NCT02315898","phase":"PHASE2","title":"Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2018-03-19","conditions":["Plastic Bronchitis","Protein-Losing Enteropathies","Healthy"],"enrollment":40,"completionDate":"2023-06-30"},{"nctId":"NCT07073469","phase":"PHASE3","title":"Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-01","conditions":["Stroke Ischemic"],"enrollment":330,"completionDate":"2027-11-01"},{"nctId":"NCT05897554","phase":"NA","title":"Intra-arterial Thrombolysis After Successful Thrombectomy for Acute Ischemic Stroke in the Posterior Circulation (IAT-TOP)","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-08-11","conditions":["Acute Ischemic Stroke","Arterial Thrombosis","Posterior Circulation Brain Infarction"],"enrollment":247,"completionDate":"2025-03-27"},{"nctId":"NCT07119021","phase":"PHASE4","title":"Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)","status":"RECRUITING","sponsor":"Ruijun Ji","startDate":"2024-08-01","conditions":["Ischemic Stroke"],"enrollment":300,"completionDate":"2027-07-31"},{"nctId":"NCT04356833","phase":"PHASE2","title":"Nebulised Rt-PA for ARDS Due to COVID-19","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-04-22","conditions":["COVID"],"enrollment":35,"completionDate":"2021-03-18"},{"nctId":"NCT07098676","phase":"","title":"Haemodialysis Alters Hypercoagulability of Blood in Dialysis Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Ai Peng","startDate":"2024-11-20","conditions":["Healthy Individuals (Controls)","Vascular Surgery Patients With Acute Thrombosis","Dialysis Patients"],"enrollment":900,"completionDate":"2026-06-30"},{"nctId":"NCT03187405","phase":"PHASE3","title":"Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage.","status":"TERMINATED","sponsor":"University Hospital, Caen","startDate":"2018-02-21","conditions":["Subarachnoid Hemorrhage"],"enrollment":81,"completionDate":"2025-02-05"},{"nctId":"NCT04920448","phase":"PHASE2","title":"N-ACETYLCYSTEINE FOR THROMBOLYSIS IN ACUTE STROKE","status":"TERMINATED","sponsor":"University Hospital, Caen","startDate":"2021-06-16","conditions":["Stroke, Ischemic"],"enrollment":12,"completionDate":"2024-04-25"},{"nctId":"NCT05657457","phase":"PHASE3","title":"Improving Neurological Outcome for Acute Basilar Artery Occlusion With Sufficient Recanalization After Thrombectomy by Intraarterial Tenecteplase (INSIST-IT)","status":"TERMINATED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2023-03-21","conditions":["Stroke, Ischemic"],"enrollment":145,"completionDate":"2025-05-18"},{"nctId":"NCT05657470","phase":"PHASE2,PHASE3","title":"Rescue Thrombolysis for Medium Vessel Occlusion (RESCUE-TNK)","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2023-03-21","conditions":["Stroke, Ischemic"],"enrollment":80,"completionDate":"2025-06-16"},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":["Acute Ischemic Stroke","Basilar Artery Occlusion"],"enrollment":224,"completionDate":"2025-12"},{"nctId":"NCT04806373","phase":"PHASE4","title":"Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis","status":"COMPLETED","sponsor":"Memorial Healthcare System","startDate":"2021-06-15","conditions":["Pleural Effusion"],"enrollment":27,"completionDate":"2023-12-14"},{"nctId":"NCT06801054","phase":"PHASE1","title":"Safety Of A Second Dose Of Tenecteplase In Selected Acute Ischemic Stroke Patients Not Responding To The First Dose","status":"NOT_YET_RECRUITING","sponsor":"Memorial Hermann Health System","startDate":"2025-07-01","conditions":["Acute Ischemic Stroke"],"enrollment":20,"completionDate":"2026-09-30"},{"nctId":"NCT06768138","phase":"PHASE3","title":"Intra-Arterial Thrombolysis After SUCCESSful Reperfusion in Anterior Circulation Ischemic Stroke","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-06-01","conditions":["Stroke, Acute Ischemic"],"enrollment":626,"completionDate":"2029-07-01"},{"nctId":"NCT06713382","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of Saline Irrigation as an Add-On Therapy for Retained Pleural Infections [LYTICS +]","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2025-04-10","conditions":["Pleural Effusion Associated With Pulmonary Infection","Pleural Effusion Disorder","Pleural Effusions"],"enrollment":96,"completionDate":"2026-12-20"},{"nctId":"NCT06187987","phase":"","title":"Mechanical Thrombectomy With the FlowTriever Device in Acute Pulmonary Embolism - a Retrospective Analysis","status":"COMPLETED","sponsor":"Kristina Svennerholm","startDate":"2023-04-01","conditions":["Pulmonary Embolism"],"enrollment":132,"completionDate":"2025-03-31"},{"nctId":"NCT04430569","phase":"PHASE3","title":"Pulmonary Embolism International THrOmbolysis Study-3","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-08-04","conditions":["Pulmonary Embolism"],"enrollment":800,"completionDate":"2028-08"},{"nctId":"NCT06769256","phase":"PHASE4","title":"Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden","status":"RECRUITING","sponsor":"Henan Institute of Cardiovascular Epidemiology","startDate":"2025-01-01","conditions":["ST-segment Elevation Myocardial Infarction (STEMI)"],"enrollment":300,"completionDate":"2026-12-30"},{"nctId":"NCT04965038","phase":"PHASE3","title":"Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2022-10-10","conditions":["Central Retinal Artery Occlusion"],"enrollment":422,"completionDate":"2026-12-31"},{"nctId":"NCT06868511","phase":"PHASE3","title":"Neuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-04-25","conditions":["Deep Intracerebral Hemorrhage (ICH)"],"enrollment":732,"completionDate":"2027-09-01"},{"nctId":"NCT06453876","phase":"PHASE3","title":"Percutaneous Embolectomy, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"Jesper Kjaergaard","startDate":"2025-06-01","conditions":["Pulmonary Embolism"],"enrollment":210,"completionDate":"2029-10-31"},{"nctId":"NCT05199194","phase":"PHASE3","title":"Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2022-05-27","conditions":["Stroke, Ischemic","Stroke, Acute"],"enrollment":398,"completionDate":"2027-07"},{"nctId":"NCT05199662","phase":"PHASE3","title":"Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2022-01-20","conditions":["Ischemic Stroke, Acute"],"enrollment":466,"completionDate":"2027-07"},{"nctId":"NCT04733742","phase":"PHASE2,PHASE3","title":"Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2022-05-09","conditions":["Stroke, Acute","Stroke, Ischemic"],"enrollment":550,"completionDate":"2025-02-07"},{"nctId":"NCT03151993","phase":"PHASE3","title":"Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS","status":"COMPLETED","sponsor":"Supergene, LLC","startDate":"2017-03-18","conditions":["Ischemic Stroke"],"enrollment":336,"completionDate":"2019-06-20"},{"nctId":"NCT04688320","phase":"PHASE3","title":"Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE","status":"COMPLETED","sponsor":"Supergene, LLC","startDate":"2020-12-15","conditions":["Massive Pulmonary Embolism"],"enrollment":310,"completionDate":"2023-07-27"},{"nctId":"NCT06571149","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-03-14","conditions":["Ischemic Stroke"],"enrollment":906,"completionDate":"2029-04-30"},{"nctId":"NCT05657444","phase":"PHASE3","title":"Intra-arterial Tenecteplase During First Thrombectomy Attempt for Acute Stroke (BRETIS-TNK II)","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2023-03-21","conditions":["Stroke, Ischemic"],"enrollment":380,"completionDate":"2025-03-20"},{"nctId":"NCT02301910","phase":"PHASE3","title":"Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI","status":"COMPLETED","sponsor":"Supergene, LLC","startDate":"2014-05-16","conditions":["Myocardial Infarction"],"enrollment":382,"completionDate":"2016-12-01"},{"nctId":"NCT05635786","phase":"","title":"Early Recanalization After Intravenous Thrombolysis With Tenecteplase Versus Alteplase in Distal Vessel Occlusion Strokes","status":"COMPLETED","sponsor":"Centre Hospitalier Sud Francilien","startDate":"2023-01-02","conditions":["Acute Distal Vessel Occlusion Stroke"],"enrollment":319,"completionDate":"2024-11-21"},{"nctId":"NCT06660719","phase":"PHASE3","title":"Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care","status":"RECRUITING","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2025-02-14","conditions":["Ischemic Stroke"],"enrollment":852,"completionDate":"2027-03-30"},{"nctId":"NCT06668441","phase":"PHASE1","title":"Minimally Invasive Surgery and RhTNK-tPA for Intracerebral Hemorrhage Evacuation","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-11-04","conditions":["Intracranial Hemorrhages","Cerebrovascular Disorders","Cerebral Hemorrhage","Hemorrhage"],"enrollment":12,"completionDate":"2025-01-27"},{"nctId":"NCT06115070","phase":"PHASE4","title":"Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":["Thrombosis","Acute Ischemic Stroke (AIS)"],"enrollment":390,"completionDate":"2028-12-31"},{"nctId":"NCT04879615","phase":"PHASE3","title":"24 Hours Treatment with Alteplase in Patients with Ischemic Stroke","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-06-21","conditions":["Stroke"],"enrollment":372,"completionDate":"2024-09-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cathflo Activase"}]},"crossReferences":{"MMSL":"4155","NDDF":"002074","UNII":"1RXS4UE564","VANDF":"4019319","INN_ID":"5975","RXNORM":"204210","UMLSCUI":"C0032143","chemblId":"CHEMBL1201593","ChEMBL_ID":"CHEMBL1201593","KEGG_DRUG":"D02837","DRUGBANK_ID":"DB00009","SNOMEDCT_US":"108997009","MESH_DESCRIPTOR_UI":"D010959"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","company":"Genentech, Inc.","brandName":"Cathflo Activase","isOriginal":true,"marketingStatus":"BLA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1996-","companyName":"Roche","relationship":"Original Developer"}],"publicationCount":3678,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"B01AD02","allCodes":["B01AD02","S01XA13"]},"biosimilarFilings":[],"originalDeveloper":"Genentech","recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Roche","companyId":"roche","modality":"Enzyme","firstApprovalDate":"1996","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T03:31:03.358816+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}